While EZH2 inhibitors show promising however moderate results as single agents in T-cell lymphomas as well as synergistic effects with other chemotherapeutics, our data do not support the combination with platinum derivates. This evidence concerns the gene EZH2 and T-cell non-Hodgkin lymphoma.